114 related articles for article (PubMed ID: 2031191)
21. Effect of whole-body hyperthermia on the pharmacokinetics and toxicity of lonidamine in dogs.
Price GS; Page RL; Riviere JE; Cline JM; Thrall DE
Int J Hyperthermia; 1995; 11(4):531-44. PubMed ID: 7594807
[TBL] [Abstract][Full Text] [Related]
22. Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer.
Young CW; Currie VE; Kim JH; O'Hehir MA; Farag FM; Kinahan JE
Oncology; 1984; 41 Suppl 1():60-5. PubMed ID: 6717897
[TBL] [Abstract][Full Text] [Related]
23. Lonidamine in metastatic breast cancer.
Rosso R; Amoroso D; Gardin G; Miglietta L; Guido T; Pace M; Repetto L; Pronzato P
Semin Oncol; 1991 Apr; 18(2 Suppl 4):62-5. PubMed ID: 2031200
[TBL] [Abstract][Full Text] [Related]
24. Lonidamine in non-small-cell lung cancer: a phase II study.
Contu A; Olmeo NA; Pani P; Deriu A; Ortu S; Paga C
Tumori; 1991 Feb; 77(1):52-5. PubMed ID: 1850177
[TBL] [Abstract][Full Text] [Related]
25. Toxicity and clinical tolerance of lonidamine.
Robustelli della Cuna G; Pedrazzoli P
Semin Oncol; 1991 Apr; 18(2 Suppl 4):18-22. PubMed ID: 2031192
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and metabolism of lonidamine in rats: evidence of enterohepatic recycling.
Besner JG; Leclaire R; Roy JJ
Drug Metab Rev; 1997; 29(1-2):219-34. PubMed ID: 9187520
[No Abstract] [Full Text] [Related]
27. Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study.
Stahl M; Schmoll E; Becker H; Schlichter A; Hoffmann L; Wagner H; Possinger K; Müller W; Köllermann M; Weidenhammer W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):33-7. PubMed ID: 2031196
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of lonidamine in inoperable non-small-cell lung cancer.
Kokron O; Maca S; Scheiner W; De Gregorio M; Ciottoli GB
Oncology; 1984; 41 Suppl 1():86-9. PubMed ID: 6717902
[TBL] [Abstract][Full Text] [Related]
29. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of VM-26 plus lonidamine in pretreated small cell lung cancer.
Gridelli C; De Marinis F; Rossi A; Tucci E; D'Aprile M; Cioffi R; Cortesi E; Migliorino R; Pisano A; Scognamiglio F; Di Giacomo R; Bianco AR
Anticancer Res; 1997; 17(2B):1277-9. PubMed ID: 9137485
[TBL] [Abstract][Full Text] [Related]
31. Lonidamine in high-risk breast cancer patients.
Possinger K; Wagner H; Kovacs S; Flath B; Classen S; Wilmanns W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):58-61. PubMed ID: 2031199
[TBL] [Abstract][Full Text] [Related]
32. The combined use of radiation therapy and lonidamine in the treatment of brain metastases.
DeAngelis LM; Currie VE; Kim JH; Krol G; O'Hehir MA; Farag FM; Young CW; Posner JB
J Neurooncol; 1989 Sep; 7(3):241-7. PubMed ID: 2677257
[TBL] [Abstract][Full Text] [Related]
33. [The antimetastatic effect of low doses of lonidamine].
Konovalova NI; Frénki F; D'iachkovskaia RF; Volkova LM
Izv Akad Nauk Ser Biol; 1995; (6):750-3. PubMed ID: 8541789
[TBL] [Abstract][Full Text] [Related]
34. Phase II evaluation of Lonidamine in patients with advanced malignancy.
Evans WK; Shepherd FA; Mullis B
Oncology; 1984; 41 Suppl 1():69-77. PubMed ID: 6717899
[TBL] [Abstract][Full Text] [Related]
35. Phase I toxicologic study of Lonidamine in cancer patients.
Band PR; Deschamps M; Besner JG; Leclaire R; Gervais P; De Sanctis A
Oncology; 1984; 41 Suppl 1():56-9. PubMed ID: 6717896
[TBL] [Abstract][Full Text] [Related]
36. An on-line semi-automated solid-phase extraction procedure for high-performance liquid chromatographic determination of lonidamine in serum.
Bottalico C; Micelli G; Guerrieri A; Palmisano F; Lorusso V; de Lena M
J Pharm Biomed Anal; 1995 Oct; 13(11):1349-53. PubMed ID: 8634352
[TBL] [Abstract][Full Text] [Related]
37. Clinical study and pharmacokinetics of lonidamine in advanced non-small cell lung cancer.
Jones AL; Hardy JR; Newell DR; Smith IE
Eur J Cancer; 1991; 27(4):519. PubMed ID: 1851622
[No Abstract] [Full Text] [Related]
38. In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.
Savini S; Zoli W; Nanni O; Volpi A; Frassineti GL; Magni E; Flamigni A; Amadori A; Amadori D
Breast Cancer Res Treat; 1992; 24(1):27-34. PubMed ID: 1463869
[TBL] [Abstract][Full Text] [Related]
39. Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1.
Scagliotti GV; Gozzelino F; Albera C; Pescetti G
Chemotherapy; 1989; 35(1):64-8. PubMed ID: 2541978
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
